At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 60 enrolled
Drug / intervention
alcaftadine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy Study of a Eye Drop for Eye Allergy
In Brief
A Phase 3 clinical trial evaluating alcaftadine and Placebo for Allergic Conjunctivitis. Completed, enrolled 60 participants across 2 sites.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of an anti-allergy eyedrop.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartApr 2009
First PostedApr 2009
Primary CompletionMay 2009
TodayJul 2026
First PostedApr 28, 2009
Enrollment StartApr 1, 2009
Primary CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 17.2 years ago
Interventions
alcaftadinedrug
0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
Placebodrug
Vehicle without active, one drop in each eye at each of two visits.